2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

By sjmartinez • October 30, 2024

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Epub ahead of print. PMID: 39471458.

Tags: covid-19, guideline, Infectious Diseases, pemivibart, Pre-exposure prophylaxis, Publications, SARS-CoV-2

Operationalizing an adverse event detection surveillance system to support antimicrobial stewardship activities: perceptions and insights from the SHEA research network

Al Lawati HJ, Harvey KL, Shin M, Mull H, Lamkin RP, Golenbock S, Basnet-Thapa D, Strymish JM, Lee M, Gold H, Bidwell Goetz M, Branch-Elliman[...]

HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084

Fogel JM, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke MA, Wang Z, Guo X, McCauley M, Farrior J, Tran HV, Ungsedhapand C, Mathew[...]

Political engagement: a key pillar in revitalisation of polio and routine immunisation programmes in the Democratic Republic of the Congo

Kamba R, El Mourid A, Mpoyi Ngambwa R, Chungu Salumu D, Le Gargasson JB, Nacoulma D, Nimpa Mengouo M, Meyer N, Luhata C, Hoff NA,[...]